Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NewBridge Pharmaceuticals Ltd.

www.nbpharma.com

Latest From NewBridge Pharmaceuticals Ltd.

Global Device Approvals, Weekly Snapshot: July 2-8, 2018

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker.

Approvals Neurology

UCB Links With Daiichi Sankyo For Epilepsy In Japan

UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.

BioPharmaceutical Japan

Deals Shaping The Medical Industry, December 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October through November 2013.

BioPharmaceutical Medical Device

Elan’s Martin Aims To Set The Record Straight About Recent Buying Spree

Changes at the Irish company have sparked a swath of media speculation and analyst interest. Elan CEO Kelly Martin used a recent fireside chat in New York to paint a clearer picture of what is going on at the company and the rationale behind its recently proposed M&A.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Parent & Subsidiaries
  • NewBridge Pharmaceuticals Ltd.
  • Senior Management
  • Joe Henein, Pres. & CEO
    G. Garrett Vygantas, MD, VP, Strategy & Bus. Dev.
    Ahmed Saeed, Dir., Mktg.
    Khaled Tamim, Dir., Fin.
  • Contact Info
  • NewBridge Pharmaceuticals Ltd.
    Phone: (966) 971 4 429 8700
    Business Central Tower A
    #2405
    P.O. Box 500618 Dubai, UAE
Advertisement
Advertisement
UsernamePublicRestriction

Register